SG11202112165QA - Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof - Google Patents
Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereofInfo
- Publication number
- SG11202112165QA SG11202112165QA SG11202112165QA SG11202112165QA SG11202112165QA SG 11202112165Q A SG11202112165Q A SG 11202112165QA SG 11202112165Q A SG11202112165Q A SG 11202112165QA SG 11202112165Q A SG11202112165Q A SG 11202112165QA SG 11202112165Q A SG11202112165Q A SG 11202112165QA
- Authority
- SG
- Singapore
- Prior art keywords
- sulfonylphenoxy
- fluoro
- methane
- propyl
- amine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19176514 | 2019-05-24 | ||
| EP20166361 | 2020-03-27 | ||
| PCT/EP2020/064046 WO2020239568A1 (en) | 2019-05-24 | 2020-05-20 | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112165QA true SG11202112165QA (en) | 2021-12-30 |
Family
ID=70682855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112165QA SG11202112165QA (en) | 2019-05-24 | 2020-05-20 | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220267262A1 (en) |
| EP (2) | EP3976581B1 (en) |
| JP (1) | JP2022533433A (en) |
| KR (1) | KR20220011638A (en) |
| CN (1) | CN113853369A (en) |
| AU (1) | AU2020286003A1 (en) |
| BR (1) | BR112021023563A2 (en) |
| CA (1) | CA3140805A1 (en) |
| CL (1) | CL2021003115A1 (en) |
| CO (1) | CO2021016556A2 (en) |
| DK (1) | DK3976581T3 (en) |
| ES (1) | ES2970361T3 (en) |
| FI (1) | FI3976581T3 (en) |
| IL (1) | IL288271A (en) |
| JO (1) | JOP20210312A1 (en) |
| MX (1) | MX2021014271A (en) |
| PT (1) | PT3976581T (en) |
| SG (1) | SG11202112165QA (en) |
| WO (1) | WO2020239568A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023548429A (en) * | 2020-11-10 | 2023-11-16 | インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー | [2-(3-Fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (methdopetam) for use in preventing or reducing sensitization to medicines for Parkinson's disease, particularly L-DOPA-induced dyskinesia |
| WO2024042540A1 (en) * | 2022-08-24 | 2024-02-29 | Alkem Laboratories Limited | Mesdopetam compositions |
| WO2024062344A1 (en) | 2022-09-21 | 2024-03-28 | Assia Chemical Industries Ltd. | Solid state forms of mesdopetam and salts therof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2612133A1 (en) | 2005-06-23 | 2006-12-28 | Astrazeneca Ab | New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases |
| PL2699543T3 (en) | 2011-04-19 | 2016-10-31 | Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission |
-
2020
- 2020-05-20 PT PT207257288T patent/PT3976581T/en unknown
- 2020-05-20 WO PCT/EP2020/064046 patent/WO2020239568A1/en unknown
- 2020-05-20 SG SG11202112165QA patent/SG11202112165QA/en unknown
- 2020-05-20 MX MX2021014271A patent/MX2021014271A/en unknown
- 2020-05-20 EP EP20725728.8A patent/EP3976581B1/en active Active
- 2020-05-20 US US17/612,902 patent/US20220267262A1/en active Pending
- 2020-05-20 KR KR1020217037818A patent/KR20220011638A/en unknown
- 2020-05-20 BR BR112021023563A patent/BR112021023563A2/en unknown
- 2020-05-20 JP JP2021569359A patent/JP2022533433A/en active Pending
- 2020-05-20 FI FIEP20725728.8T patent/FI3976581T3/en active
- 2020-05-20 JO JOP/2021/0312A patent/JOP20210312A1/en unknown
- 2020-05-20 CN CN202080036829.0A patent/CN113853369A/en active Pending
- 2020-05-20 DK DK20725728.8T patent/DK3976581T3/en active
- 2020-05-20 AU AU2020286003A patent/AU2020286003A1/en active Pending
- 2020-05-20 ES ES20725728T patent/ES2970361T3/en active Active
- 2020-05-20 CA CA3140805A patent/CA3140805A1/en active Pending
- 2020-05-20 EP EP23190702.3A patent/EP4292653A3/en active Pending
-
2021
- 2021-11-21 IL IL288271A patent/IL288271A/en unknown
- 2021-11-24 CL CL2021003115A patent/CL2021003115A1/en unknown
- 2021-12-06 CO CONC2021/0016556A patent/CO2021016556A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3976581B1 (en) | 2023-11-22 |
| FI3976581T3 (en) | 2024-01-31 |
| US20220267262A1 (en) | 2022-08-25 |
| EP4292653A3 (en) | 2024-04-24 |
| DK3976581T3 (en) | 2024-01-22 |
| AU2020286003A1 (en) | 2021-12-02 |
| BR112021023563A2 (en) | 2022-01-04 |
| CN113853369A (en) | 2021-12-28 |
| CL2021003115A1 (en) | 2022-09-30 |
| WO2020239568A1 (en) | 2020-12-03 |
| MX2021014271A (en) | 2022-01-06 |
| KR20220011638A (en) | 2022-01-28 |
| PT3976581T (en) | 2024-02-08 |
| EP4292653A2 (en) | 2023-12-20 |
| JP2022533433A (en) | 2022-07-22 |
| IL288271A (en) | 2022-01-01 |
| CA3140805A1 (en) | 2020-12-03 |
| ES2970361T3 (en) | 2024-05-28 |
| CO2021016556A2 (en) | 2022-01-17 |
| JOP20210312A1 (en) | 2023-01-30 |
| EP3976581A1 (en) | 2022-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288271A (en) | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof | |
| EP3807279A4 (en) | Pharmaceutically acceptable salts of sepiapterin | |
| IL288062A (en) | Solid state forms of tafamidis and salts thereof | |
| ZA201307688B (en) | Pharmaceutically acceptable cocrystals of n-[2-(7-methoxy-1-naphtyl)ethyl] acetamide and methods of their preparation | |
| EP3750890A4 (en) | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | |
| EP3943488A4 (en) | Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof | |
| EP4006024A4 (en) | Heterocyclic amide compound, preparation method therefor and use thereof | |
| EP3915973A4 (en) | Compound for preparation of antibody-payload conjugate and use thereof | |
| EP3677575A4 (en) | Crystalline form of ozanimod hydrochloride and preparation method therefor | |
| EP3903827A4 (en) | Use of rifamycin-quinolizidone coupling molecule and pharmaceutically acceptable salt thereof | |
| EP4013398A4 (en) | An improved process for preparation of vilanterol or a pharmaceutically acceptable salt thereof | |
| IL289786A (en) | Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof | |
| EP3845530A4 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| IL281168A (en) | Crystalline forms of a quinazole compound and its hydrochloride salts | |
| EP3867222A4 (en) | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | |
| IL240136A0 (en) | Pharmaceutical composition comprising n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof | |
| ZA202101652B (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
| GB202212116D0 (en) | Pharmaceutically acceptable salts and Compositions thereof | |
| EP3938370A4 (en) | Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof | |
| IL281080A (en) | Compositions comprising a selenite-containing compound and a pharmaceutically acceptable acid for treating human papillomavirus infections | |
| IL283843A (en) | (s)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof | |
| SG10201912268UA (en) | Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | |
| EP3653602A4 (en) | N-(2-(substituted-naphth-1-yl)ethyl) substituted amide compound, preparation and uses thereof | |
| PL3643704T3 (en) | New intermediates for the preparation of remifentanil hydrochloride | |
| ZA202008062B (en) | Pharmaceutically acceptable salts of sepiapterin |